Multiple myeloma is caused by faulty activation of growth genes. In this project, Christopher Ott aims to develop new therapeutics that target the factors driving this malfunctioning expression. He and his group will develop tools to study the myeloma epigenome and to nominate new strategies for drug development.
Content courtesy of Gabrielle’s Angel Foundation for Cancer Research